{
    "symbol": "MRNA",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-03 13:02:01",
    "content": " Good morning, or good afternoon, everyone. Good morning, or good afternoon, everyone. Total product sales for the second quarter of 2022 of $4.5 billion, increased by $334 million or 8% compared to the prior period. Total revenue was $4.7 billion for the second quarter of 2022, an increase of $395 million compared to Q2 of last year, driven by the increase of sales of our COVID-19 vaccine. Total product sales for the first six months of 2022 were $10.5 billion, increased by $4.5 billion or 76% compared to the prior year period. Research and development expenses were $1.3 billion for the first six months of 2022, an increase of $442 million or 54% compared to the prior year. First to execute on delivering vaccine against $21 billion of Advanced Purchase Agreements, with half of the year behind us and the sign deals for the fall of 2022 and a strong manufacturing team we are on target. Your line is open. Your line is open. One moment for our next question. One moment for our next question. Your line is open. One moment for our next question. Your line is open. One moment for our next question. Your line is open. One moment for our next question. Your line is open."
}